FTC: 12- to 14-year exclusivity for biotech drugs too long

06/10/2009 | Reuters

The 12- to 14-year market exclusivity sought by biotech drugmakers to protect their brand name products is too long because it will stifle innovation and chances are these companies will keep "a substantial market share" when generic counterparts gain FDA approval, according to a Federal Trade Commission report. Follow-on biologics are unlikely to be discounted more than 10% to 30% off the price of brand name medicines, according to the report.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD